This finding has triggered the development of heterodimeric radioligands, which are able to target both the GRPR and PSMA in prostate cancer lesions, thereby, increasing diagnostic sensitivity and therapeutic efficacy [84,105,106,107]. Here, FOLH1 is linked to prostate cancer.